DORMANT studio
localhost:3000

Opportunity radar

4,186,134 patents indexed · 165,974,948 citations · issued 2005-01-04 → 2026-05-05

Showing50 of 30,252
Free-text
CPC starts with (comma sep)
Min fwd citations
Clear
Patent #TitleAssetsIssuedExpiresFwd citesScore
12617757Compounds and modules for inhibition of pre-miR-21 and their use in treatment of certain cancers🖼🧊📄§2026-05-052040-10-29031
12617759Modifier of four-membered ring derivative, preparation method and application thereof🖼🧊📄§2026-05-052040-10-29031
12617792Purine derivative, intermediate and application thereof in preparing anticancer medicine🖼🧊📄§2026-05-052040-10-21031
12617762Carboxy derivatives with antiinflamatory properties🖼🧊📄§2026-05-052040-12-23031
12617790Mitragynine analogs and uses thereof🖼🧊📄§2026-05-052041-06-24031
12617805Codrug that disintegrates in intestine, preparation therefor, and use thereof🖼🧊📄§2026-05-052041-07-19031
12617807Long lasting opioid reversal using hydrogen peroxide-induced release in blood🖼🧊📄§2026-05-052042-04-01031
12617809Cardioprotective lipid and method of use🖼🧊📄§2026-05-052042-09-22031
12617811HPK1 inhibitors and uses thereof🖼🧊📄§2026-05-052041-07-02031
12617812Platinum(IV) complexes, methods of manufacture, compositions containing, and methods of use thereof🖼🧊📄§2026-05-052042-05-25031
12617820Engineered coronavirus spike (s) protein and methods of use thereof🖼🧊📄§2026-05-052041-05-28031
12617823Broad-spectrum peptide antigen of the novel coronavirus SARS-COV-2, specific neutralizing antibody and use thereof🖼🧊📄§2026-05-052041-07-21031
12617826CLEC2 fusion protein and uses thereof🖼🧊📄§2026-05-052041-09-29031
12617828Genetically modified immune cell, preparation method therefor, and application🖼🧊📄§2026-05-052040-05-06031
12617831Peptide targeting GIP and GLP-2 receptors for treating bone disorders🖼🧊📄§2026-05-052040-02-21031
12617836Tumor environment specific expression of effector genes🖼🧊📄§2026-05-052042-03-21031
12617841Nucleic acid antibody constructs for use against respiratory syncytial virus🖼🧊📄§2026-05-052039-01-31031
12617843Human broadly neutralizing antibodies against the membrane-proximal external region of HIV Env for vaccine design and intervention🖼🧊📄§2026-05-052040-10-14031
12617850Treatment of PD-L1-positive melanoma using an anti-PD-1 antibody🖼🧊📄§2026-05-052042-03-22031
12617849Antigen specific CD19-targeted CAR-T cells🖼🧊📄§2026-05-052040-04-29031
12617851TREM2 antibodies and uses thereof🖼🧊📄§2026-05-052042-05-05031
12617856Protease-cleavable substrates and methods of use thereof🖼🧊📄§2026-05-052045-03-17031
12617864Methods of activating and proliferating exhausted CD8 T cells, CD8 T cells with enhanced activity prepared by the same, and uses thereof🖼🧊📄§2026-05-052042-04-12031
12617866Humanized antibodies to mucin-16 and methods of use thereof🖼🧊📄§2026-05-052040-05-07031
12617868Activation of (Na++K+)-ATPase inhibits platelet aggregation and prevents thrombosis🖼🧊📄§2026-05-052042-11-08031
12617870Methods of reversing ticagrelor activity🖼🧊📄§2026-05-052039-09-20031
12617755Compositions and methods for treating metabolic disease🖼🧊📄§2026-05-052040-08-03031
12617769Chemical compound as thyroid hormone beta receptor agonist and use thereof🖼🧊📄§2026-05-052040-09-23031
12618838Single domain VHH antibodies against SARS-CoV-2 virus🖼🧊📄§2026-05-052042-11-15031
12617862Anti-CD73 antibody and application thereof🖼🧊📄§2026-05-052040-08-20031
12618031Delivery devices🖼🧊📄§2026-05-052041-06-24031
12616742Recombinant heme oxygenase-1 (HO-1) for the treatment of sickle cell disease🖼🧊📄§2026-05-052040-07-24031
12616684Pulmonary fibrosis medicine containing pyrazole derivative🖼🧊📄§2026-05-052041-03-23031
12616705Use of cannabinoids in the treatment of Angelman syndrome🖼🧊📄§2026-05-052043-05-02031
12616706Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations🖼🧊📄§2026-05-052040-03-06031
12616761CXCR4-targeting compounds🖼🧊📄§2026-05-052044-06-27031
12616741Therapeutic combination comprising a pulmonary surfactant and a steroid for the prophylaxis of BPD🖼🧊📄§2026-05-052041-03-17031
12620468Personalized liver cancer treatment🖼🧊📄§2026-05-052045-03-06031
12616681Compositions and methods for treating renal injury🖼🧊📄§2026-05-052042-08-22031
12616677Injectable pharmaceutical compositions and uses thereof🖼🧊📄§2026-05-052040-05-01031
12616678Methods to of aldehyde dehydrogenases for treatment of cancer🖼🧊📄§2026-05-052041-06-10031
12616689Regimens of tafenoquine for prevention of malaria in malaria-naive subjects🖼🧊📄§2026-05-052043-08-30031
12616690Specific AKT3 activator and uses thereof🖼🧊📄§2026-05-052044-03-15031
12616687Treatment of viral infection, disease or disorder using a selective sir agonist🖼🧊📄§2026-05-052042-11-04031
12616700Therapeutic regimen🖼🧊📄§2026-05-052043-07-07031
12616698Methods for reducing liver fat and for treating fatty liver disorders🖼🧊📄§2026-05-052043-11-22031
12616697Methods of treatment with myosin modulator🖼🧊📄§2026-05-052041-08-26031
12616709Pharmaceutical composition for treating sepsis and use thereof🖼🧊📄§2026-05-052041-03-23031
12616708Methods for treating pulmonary non-tuberculous mycobacterial infections🖼🧊📄§2026-05-052044-11-07031
12616710Topical compositions🖼🧊📄§2026-05-052045-07-23031